Találati lista | Tudóstér

001-es BibID:	BIBFORM113525
035-os BibID:	(scopus)85153198683 (wos)000973515200001
Első szerző:	Mrukwa-Kominek, Ewa
Cím:	A randomized clinical trial comparing three fixed combinations of bimatoprost with timolol in patients with open-angle glaucoma or ocular hypertension / Mrukwa-Kominek Ewa, Misiuk-Hojlo Marta, Csutak Adrienne, Stalmans Ingeborg, Garhofer Gerhard
Dátum:	2023
ISSN:	0300-7995
Megjegyzések:	Objective: To compare the efficacy and safety of two fixed combination, preservative-free eye drops (bimatoprost 0.01% in combination with either timolol 0.1% or 0.5%) in a gel formulation, with bimatoprost 0.03%/timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Methods: Phase II, randomized, investigator-masked, multicenter, 3-arm parallel group (Eudract No. 2017-002823-46). Eighty-six patients aged >= 18 years with OAG or OHT, with intraocular pressure (IOP) initially controlled for at least 6months by a combination therapy of a dual prostaglandin and timolol or insufficiently controlled by first-line monotherapy were included. Patients were randomized to receive T4030a (bimatoprost 0.01%/timolol 0.1%; N = 29), T4030c (bimatoprost 0.01%/timolol 0.5%; N = 29) or bimatoprost 0.03%/timolol 0.5% (N = 28), administered once daily in the evening for 12 weeks. Primary endpoint was defined as change in IOP from day 1 to week 12 measured at 08:00 (+/- 1 h). Further efficacy, safety and pharmacokinetic endpoints were assessed as secondary outcomes. Results: The mean change in IOP from baseline to week 12 was -9.8 +/- 2.1mmHg for T4030a, -10.1 +/- 2.5mmHg for T4030c and -10.0 +/- 2.8mmHg for bimatoprost 0.03%/timolol 0.5%. All treatments were well tolerated with no safety issues identified in any group. In patients treated with T4030a, the systemic concentration of timolol was significantly lower after 12 weeks than in patients treated with T4030c or bimatoprost 0.03%/timolol0.5%. Conclusions: These study results suggest that the preservative-free ophthalmic formulation of T4030a (bimatoprost 0.01%/timolol 0.1%) can be regarded as a useful tool in the therapeutic management of OAG and OHT.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Current Medical Research And Opinion. - 39 : 5 (2023), p. 775-783. -
További szerzők:	Misiuk-Hojlo, Marta Csutak Adrienne (1971-) (szemész) Stalmans, Ingeborg Garhofer, Gerhard
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: